Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 08:15:20 2024-03-28 am EDT 5-day change 1st Jan Change
38.1 CHF +0.93% Intraday chart for Basilea Pharmaceutica AG +7.16% +8.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Basilea Pharmaceutica to Receive Milestone Payment from Pfizer for Antifungal Drug MT
Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ
Stronger-than-Expected US Inflation Rate Weighs on Swiss Equities MT
Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2024 CI
Transcript : Basilea Pharmaceutica AG, 2023 Earnings Call, Feb 13, 2024
Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Basilea Pharmaceutica Posts Lower FY23 Net Profit; Revenue Up MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea MT
Basilea Pharmaceutica to Receive First Milestone Payment for Cresemba from Latin America MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis MT
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health... Our Logo
Basilea Pharmaceutica Eyes Commercialization Partner for Ceftobiprole Ahead of US FDA Verdict MT
Global markets live: Fedex, Curevac, Shell, Fedex, Alphabet... Our Logo
Basilea Pharmaceutica Plans Early Repayment of Loan from Athyrium Capital MT
Basilea Pharmaceutica Ltd Announces Accelerated Loan Repayment CI
Basilea Pharmaceutica License Partner Obtains US FDA Approval for Expanded Use of Antifungal Medication MT
Swiss Equities Little Changed Amid Economic Data Spotlight, Julius Bär’s Profit Woes MT
Basilea to Get $1 Million Sales Milestone Payment from Pfizer for Antifungal Drug MT
Swiss Equities Rise as Unemployment Rate Falls MT
Basilea Pharmaceutica Revises Revenue Guidance for the Full Year 2023 CI
Transcript : Basilea Pharmaceutica AG - Special Call
Pfizer: Amplyx transfers antifungal rights to Basilea CF
Basilea to Buy Investigational First-in-Class Antifungal Drug from Pfizer Affiliate MT
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON MT
Basilea Pharmaceutica to Buy Clinical-stage Antifungal Compound from Gravitas Therapeutics MT
Chart Basilea Pharmaceutica AG
More charts
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
37.75 CHF
Average target price
69.08 CHF
Spread / Average Target
+83.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Basilea Pharmaceutica AG - Swiss Exchange
  4. News Basilea Pharmaceutica AG
  5. Basilea Pharmaceutica : EB1 Shows Long-Lasting Benefit in Glioblastoma Cancer Patients